162results about "Radiosensitized materials" patented technology

The invention belongs to the technical field of engineered probiotics, and particularly relates to engineered probiotics for radiosensitization and tumor metabolism regulation as well as a preparation method and application of the engineered probiotics. The engineering probiotics comprise probiotics and core-shell type metal nanoparticles which are loaded on the probiotics and are synthesized through a biological directional mineralization effect; the core of the core-shell type metal nanoparticle is a palladium element, and the outer layer of the core-shell type metal nanoparticle is a palladium element and a gold element. The engineering probiotics provided by the invention have excellent enzyme catalysis performance and can target and retain in tumor sites, and through the synergistic effect of all components in the engineering probiotics, adenosine metabolism is effectively inhibited, secretion of pro-inflammatory cytokines is enhanced, tumor microenvironment is promoted to be converted into an inflammatory state, up-regulation of immune checkpoints is inhibited, and the immune checkpoints are inhibited. And T cells are inhibited from being transformed into depletion phenotype and transformed into effect type from depletion type. After the SBRT and the immune checkpoint inhibitor are combined for use, the growth of tumors can be effectively inhibited, and the effect of enhancing immune radiotherapy is achieved.

The invention belongs to the field of catalytic materials, and particularly relates to a multi-enzyme activity high-entropy alloy material and a preparation method and application thereof. The multi-enzyme activity high-entropy alloy material comprises the following components: Ga, Pd, Ru, Ir and Mn, wherein the crystal phase structure of the high-entropy alloy material is a single-phase solid solution structure. The multi-enzyme activity high-entropy alloy material provided by the invention has pH-adaptive multi-enzyme activity, and not only can effectively treat tumors, but also can protect damage caused by radiotherapy.

Method and kit for topical treatment of a skin infection, in particular of superficial skin infections, caused by Staphylococcus aureus. The method comprises the steps of applying a photosensitizer to at least a part of the skin affected by the infection, and subjecting said part of the skin to first photons with a majority energy between 2.8 eV and 3.5 eV at a first energy level; and second photons with a majority energy between 1.24 eV and 1.65 eV at a second energy level, the ratio between the first and the second energy levels being in the range from about 10:1 to 2:1. By the method efficient treatment of Staphylococcus aureus infections can be achieved without the administration of topical antibiotics.

The invention relates to the technical field of traditional Chinese medicine nano preparations, in particular to traditional Chinese medicine polysaccharide radiotherapy sensitization nanoparticles and a preparation method thereof.The preparation method comprises the following steps that 1, a chitosan-based carrier and traditional Chinese medicine polysaccharide are dissolved in a buffer solution, and the chitosan-based carrier is selected from chitosan, carboxymethyl chitosan or quaternized chitosan; step 2, putting the chitosan-based carrier solution into a reaction container, and dropwise adding glacial acetic acid to adjust the pH value of the system; 3, a cross-linking agent solution is dropwise added at a constant speed, a cross-linking agent is a multivalent anion / cation compound, and stirring is performed to form a core-shell structure; step 4, dropwise adding a traditional Chinese medicine polysaccharide solution into a mixed system in the step 3, and continuously stirring; step 5, filtering and granulating the obtained solution to obtain nanoparticles; according to the traditional Chinese medicine polysaccharide radiotherapy sensitization nanoparticles and the preparation method thereof, not only is radiotherapy sensitization achieved, but also the immunoregulation function is achieved, and the synergistic interaction of radiotherapy and immunotherapy is achieved by activating dendritic cells and T cells.

A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

The invention belongs to the field of medicines, and particularly relates to a nanosheet capable of activating an STING pathway and improving microwave ablation as well as a preparation method and application of the nanosheet. The nanosheet is prepared from MXenes through organic acid treatment, organic alkali dispersion, STING agonist compounding and phospholipid modification, and has good microwave thermal conversion efficiency and an STING pathway activation function. The combined microwave ablation can enhance the immunogenic death of tumor cells, promote the maturation of dendritic cells, doubly activate immune response and effectively inhibit the growth and metastasis of prostatic cancer, provides a new strategy for the treatment of prostatic cancer, and can be used for preparing drugs for treating prostatic cancer.

The present application relates to a kind of radiotherapy sensitization microneedle and its preparation method and application, belong to biological medicine technical field.The radiotherapy sensitization microneedle of the present application includes hyaluronic acid and nano radiosensitizer;The radiotherapy sensitization microneedle is obtained by drying after hyaluronic acid and nano radiosensitizer solution are mixed;The nano radiosensitizer solution is prepared by the following method: hafnium salt, 1,1'-ferrocene dicarboxylic acid and benzoic acid are mixed in organic solvent and stirred, centrifugal;The supernatant obtained is dialyzed, extracted, and the liquid phase obtained after solid-liquid separation is nano radiosensitizer solution.The radiotherapy sensitization microneedle of the present application is applied to the growth inhibition and radiotherapy sensitization of mouse melanoma cell B16F10 cell, can fully play the role of radiotherapy sensitization while overcoming the limitation of prior art, and preparation route is simple, and have certain conversion prospect.

The present disclosure relates generally to methods of utilizing sonosensitizers in the presence of thiamine or a derivative thereof for the purpose of cross-linking animal tissue, producing singlet oxygen within or at the site of animal tissue, or treating a condition in a subject, wherein the condition is an aneurysm, cancer, and / or a scleral condition.

Disclosed herein are boronated amino acid compositions comprising tyrosine derivatives TC220 and TC221 and improved methods of making TC220 and TC221. Thus, the TC220 and / or TC221 can be expanded to commercial scale and administered to patients as neutron trapping agents, and methods of treating cancer, immune disorders, and other diseases by utilizing a neutron capture therapy pattern are provided.

The invention relates to an application of a DNAJB4 gene and an encoding protein thereof in preparation of a product for enhancing cancer radiotherapy sensitivity. The DNAJB4 gene provided by the invention is closely related to cancer radiotherapy sensitivity, and overexpression of the DNAJB4 gene is positively related to radiotherapy sensitivity of head and neck squamous cell carcinoma, cervical cancer or breast cancer. A product prepared from the target DNAJB4 selectively degrades DNA-PKcs through a CMA way, high specificity is achieved, and toxicity to normal tissue can be reduced; the radiotherapy remission rate of a patient with high DNAJB4 expression is obviously improved (clinical queue data); the combined treatment prolongs the median lifetime of the mouse model; the drug resistance risk can be reduced by combining with existing therapies (radiotherapy and immunotherapy).

The present invention relates to the treatment of viral infections using photosensitizers in dairy cattle. The invention also relates to the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species. The invention is also directed to methods of controlling infectious agents on milking equipment for dairy cattle. The invention is further directed to milking processes including the treatment of viral infections and / or the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species and / or the methods for controlling infectious agents on milking equipment for dairy cattle.

A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor.

The application belongs to the technical field of biomedical engineering, and specifically discloses a nano gene composition for treating brain glioma and a preparation method thereof, which is synthesized from bovine serum albumin loaded manganese dioxide particles, PLGA, DSPE-PEG3000 and DSPE-PEG-Angiopep2 as raw materials; the average particle size of the nano gene composition is 122.18±31.3 nm. The application also discloses a preparation method of the nano gene composition. The nano gene composition provided by the application encapsulates miRNA-138 in PLGA to avoid the degradation of miRNA-138 by RNA enzymes in the body, and simultaneously utilizes the targeting property of Angiopep2 to target the delivery of the nano gene composition to tumor tissues, to deliver microRNA into the brain while reducing tumor hypoxia and increasing the sensitivity of cells to X-ray irradiation, so as to realize multidirectional comprehensive treatment of glioblastoma.

The application discloses a lanthanide rare earth nano probe and a preparation method and application thereof, the probe is RENPs, the RENPs take NaNdF4:Yb@NaLuF4 as an imaging element, and the plerixafor is a targeting element.The application provides a lanthanide rare earth nano probe and a preparation method and application thereof, takes NaNdF4:Yb@NaLuF4 as an imaging element, and the small-molecule drug plerixafor is a targeting element, both are combined radiotherapy sensitization elements, a rare earth nano probe RENPs with good biocompatibility and stable NIR-Ⅱ luminescence is constructed, the probe can visualize breast cancer before radiotherapy, so that precise radiotherapy target delineation can be carried out, the sensitivity of tumor cells to radiation is improved during radiotherapy, so that the sensitivity of radiotherapy is improved, the anti-tumor immunity of the body is activated, and the treatment of the anti-PD-L1 immune checkpoint inhibitor in combination can effectively improve the immunotherapy responsiveness, and the prognosis of metastatic and recurrent triple-negative breast cancer patients who lose the opportunity of surgery is improved.

The invention discloses a tellurium-based nano material capable of efficiently inducing copper death as well as a preparation method and application of the tellurium-based nano material. The preparation method comprises the following steps: by taking water as a medium, mixing soluble copper salt and a sulfydryl-containing compound, and stirring to react, so as to obtain a Cu-S2 solution; dropwise adding the Cu-S2 solution into the TeO2 nano-carrier solution, and carrying out stirring reaction; and after the reaction is finished, carrying out solid-liquid separation, taking the solid, and resuspending with methanol to obtain the TeO2 coated Cu-S2 nano material. The preparation method is simple and rapid, large-scale production can be achieved, and the obtained TeO2 coated Cu-S2 nano material can efficiently induce cancer cells to generate copper death, is effective to various cancer cells and has potential clinical transformation application prospects.

Provided is a Pt(IV) complex. As a prodrug, the Pt(IV) complex is activated by irradiation to release a Pt(II) complex for the treatment of tumors. Also provided is a pharmaceutical composition including the Pt(IV) complex, and the use of the Pt(IV) complex in the preparation of a drug for treating tumors by means of irradiation activation. Further provided is a kit including the Pt(IV) complex and the description, wherein the description indicates that radiotherapy is performed after administration to treat tumors.

The present invention relates to a supramolecular peptide complex comprising several peptide oligomerisation domains capable of forming multivalent complexes, bonded to at least one antigen-binding molecule and to at least one chelating group binding at least one metal cation of a heavy metal (M) having an oxidation state (M2+, M3+, M4+).

The invention discloses a kind of artificial metabolic enzyme targeting mitochondria and its preparation method and application, relate to the field of biomedical material technology, the method comprises the following steps:Activated carbon is mixed and stirred with phosphomolybdic acid solution to obtain POM / AC;Mixed with acetylacetonate platinum (II) solution, reduction treatment is carried out to obtain Pt-POM / AC;It is dispersed in ethanol, 3-aminopropyltriethoxysilane is added and stirred, and solid A is obtained by freeze drying;(3-carboxypropyl) triphenylphosphine bromide, dimethyl sulfoxide and 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride are mixed, stirred in dark, N-hydroxysuccinimide is added, activated in dark, and solution B is obtained;Solid A is dissolved, mixed with solution B, stirred in dark, centrifuged, washed and dried, and the artificial metabolic enzyme targeting mitochondria is obtained.The artificial metabolic enzyme can be effectively taken up by tumor cells, and combined radiotherapy anti-tumor effect is better, and there is greater application value.

The present invention discloses a dual-targeted macrophage membrane nanosystem, its preparation method and application, which belongs to the field of biomedicine. MKA is formed by connecting AuNPs with the mitochondrial targeting peptide KLA and then encapsulating it in the macrophage membrane. During preparation, AuNPs are first synthesized and modified, and then encapsulated with the macrophage membrane. During treatment, it can dual-target tumor cells and mitochondria, enhance radiation-induced DNA damage, inhibit DDR, activate immune pathways, promote T cell infiltration, and consume glutathione and amplify oxidative stress to enhance immune effects. The dose enhancement ratio synergistic with 8GyX-rays is 3.1. In addition, MKA has good biocompatibility in the body, a long blood circulation time, high tumor targeting, and can be quickly cleared through the kidneys. This invention provides a new approach for tumor radioimmunotherapy and helps promote progress in clinical tumor treatment.

Borylated Amino Acid compositions comprising tyrosine derivatives TC220 and TC221 and improved methods of making TC220 and TC221 are disclosed herein. Consequently, the TC220 and / or TC221 can be scaled up to commercial scale and administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders, and other disease by utilizing a Neutron Capture Therapy modality.

Provided are a fluorine-18-labeled positron emission tomography (PET) radiotracer for diagnosing neuroinflammation, stroke or cerebral infarction and a method for diagnosing cancer in a subject including administering a fluorine-18-labeled PET radiotracer a subject, obtaining in vivo PET images of the uptake of the fluorine-18-labeled positron emission tomography (PET) radiotracer in a lesion in the subject, and evaluating the uptake of the fluorine-18-labeled radiotracer in the lesion.

The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and / or therapy.The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRD and / or in other diagnostic techniques and / or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.Thus, the nanoparticles according to the invention, with diameter d1 between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations optionally associated with doping cations; a chelating graft C1 DTPABA (diethylenetriaminepentaacetic acid bisanhydride) bound to the POS matrix by an —Si—C— covalent bond, and present in sufficient quantity to be able to complex all the gadolinium cations; and optionally another functionalizing graft Gf* bound to the POS matrix by an —Si—C— covalent bond (where Gf* can be derived from a hydrophilic compound (PEG); from a compound having an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein).The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.

Described herein are combination therapies featuring [177Lu]Lu-PSMA-617 and a DNA Damage Response inhibitor (DDRi), and their use in treating cancers, such as, e.g., PSMA-expressing cancers.

The present invention relates to a micelle complex and a drug carrier. By supporting hydrophobic manganese oxide particles in the micelles, the complex is stably protected in vivo and easily delivered to a tumor site. Further, the micelles have a hydrophilic portion and a hydrophobic portion bound by a reactive oxygen species (ROS) cleavable linker in order to be degraded in response to a reactive oxygen species of a target site, and thus can efficiently release the hydrophobic manganese oxide particles. The released hydrophobic manganese oxide particles generate oxygen and changes the microenvironment of the target site, and thus may enhance the therapeutic effect of a drug carried on the micelles.

This invention relates to the field of biomedical technology. The invention discloses a method for preparing nanomaterials that can improve the radiosensitivity of tumors and their applications, comprising: S1: dissolving tungsten and copper compounds in an organic solvent in a specific ratio to prepare a mixed solution; S2: transferring the solution to a reaction vessel, adding a surfactant or polymer, and reacting at a certain temperature to form rod-shaped initial nanomaterials; S3: cooling to room temperature, centrifuging and washing to obtain a moist material; S4: drying to obtain Cu-W. 18 O 49 Nanomaterials. The Cu-W of this invention 18 O 49 Nanomaterials can be injected intravenously or intratumorally to target tumors via the EPR effect. When combined with near-infrared light and X-ray therapy, the photothermal effect raises the temperature, improves hypoxia, and enhances the killing effect of radiotherapy. It is suitable for triple-negative breast cancer, etc., inhibiting tumors through the secondary electrons of tungsten, the Fenton reaction of copper ions, and the photothermal effect. It can be monitored by CT or photoacoustic imaging, and can activate the immune response when used in combination with immune checkpoint inhibitors.

Methods of treatment and treatment systems for performing radiomodulatory stereotactic radiosurgery to treat brain disorders in which target neural tissues associated with the brain disorder are sensitized to radiation by administration of a molecular substance and / or non-targeted critical structures are protected from radiation by a molecular substance, in order to treat disorders of brain circuitry. Specific embodiments disclose means for treating pain, obesity and drug addiction.

To provide a fractionated dosing regimen of 131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer.SOLUTION: A fractionated dosing regimen of 131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer provides better tolerability than an equivalent single total dose administration and reduces the mean grade of adverse events, thereby contributing to site-specific eradication of malignant tumor tissue.SELECTED DRAWING: Figure 7

The present invention is in the field of pre-functionalized nanoparticles (NPs). It more particularly relates to the use of NPs pre-functionalized with self-assembled monolayers (SAMs), and also to the use of NPs functionalized with biomolecules, such that the NPs are stable in solution. These NPs can be used in a variety of applications, in particular as diagnostic tools, depletion tools of target molecules in solution, and therapeutic tools.